close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

50.99 +0.09 (+0.18%)
Official Closing Price Updated: 7:00 PM EDT, May 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
45 46 Next >
News headline image
Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs ↗
Discover Cantor Fitzgerald's analysis on Innoviva, highlighting its unique royalty-based business model with GSK for asthma and COPD products. 
Via Benzinga
News headline image
7 A-Rated Biotech Stocks Worth Betting on in June ↗
A-rated biotech stocks are highly coveted because they are at the forefront – or in the midst of -- groundbreaking innovation. 
Via InvestorPlace
News headline image
3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition ↗
Don’t miss out on these three penny stocks, which have amazing potential to take off following upcoming business developments this year. 
Via InvestorPlace
News headline image
Moderna Says Combination Flu And Covid Vaccine Beat Out Rivals From Sanofi, GSK ↗
If approved, this would be the first combination vaccine based on mRNA technology to hit the market. 
Via Investor's Business Daily
News headline image
US FDA Approves Expanded Age Indication for GSK’s AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk
From GSK plc
Via Business Wire
News headline image
The 3 Most Undervalued Pharma Stocks to Buy in June 2024 ↗
These undervalued pharma stocks to buy are worth a look because even when the economy is struggling, consumers need key medicines. 
Via InvestorPlace
Topics Economy
News headline image
Large Cap BIopharmaceuticals Overview ↗
As a defensive play healthcare is weighted at about 12% of the S&P 500. 
Via Talk Markets
Topics Stocks
News headline image
GSK Stock Falls as 70,000 Zantac Lawsuits Move Forward. What to Know. ↗
Investors in GlaxoSmithKline are seeing a lot of red on their screens today, as GSK stock falls more than 8% on big legal news. 
Via InvestorPlace
Topics Lawsuit
News headline image
GSK's Blenrep Combo Therapy Cuts Risk Of Disease Progression Or Death By Around 50% In Pretreated Multiple Myeloma ↗
GSK presented interim results from the DREAMM-8 phase 3 trial at ASCO 2024. Blenrep (belantamab mafodotin) with PomDex showed a significant improvement in progression-free survival for relapsed or... 
Via Benzinga
News headline image
Zantac Heart Burn Continues For GSK As US Court Ruling Allows Thousands Of Zantac Lawsuits To Move Forward ↗
GSK shares fell as the Delaware State Court allowed over 70,000 lawsuits regarding the discontinued heartburn drug Zantac (ranitidine) to proceed. This ruling contradicts a Federal Court's 2022... 
Via Benzinga
Topics Lawsuit
News headline image
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
News headline image
GSK, Boston Beer And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer
From GSK plc
Via Business Wire
News headline image
Is Moderna Stock a Buy Now That It's a 2-Product Company? ↗
The Food and Drug Administration recently approved a new vaccine from Moderna, but the stock dipped in response. 
Via The Motley Fool
News headline image
Why GameStop Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
From GSK plc
Via Business Wire
News headline image
Moderna Wins FDA Approval For Second-Ever Product; Why Its RSV Vaccine Could Dominate Pfizer, GSK ↗
Moderna's RSV vaccine will launch a year behind Pfizer and GSK, but it could become the market leader over the next five years. 
Via Investor's Business Daily
News headline image
AstraZeneca, Merck, GSK Struck Record $44.1B Licensing Deals With Chinese Drugmakers In 2023: Report ↗
Western pharmaceutical companies and investors are driving a record number of licensing deals with Chinese drugmakers. 
Via Benzinga
News headline image
Zantac Verdict: Jury Finds No Link To Colon Cancer In Initial Trial, GSK And Boehringer Prevail In First Zantac Cancer Lawsuit ↗
Chicago jury rejects woman's claim that Zantac caused her colon cancer. First of thousands of similar lawsuits, companies deny scientific evidence. 
Via Benzinga
Topics Lawsuit
News headline image
First Advanced Oral Treatment For Asthma - Sanofi's Investigational Drug Shows Potential ↗
Sanofi reveals Phase 2 results for rilzabrutinib in moderate-to-severe asthma. High and low doses showed a reduction in asthma control loss events and symptom improvements. 
Via Benzinga
News headline image
GSK Concealed Risk Associated With Discontinued Heart Burn Drug Zantac, Whistleblower Lawsuit Claims ↗
Valisure sues GSK accusing the company of hiding cancer risks linked to Zantac, potentially defrauding the U.S. government. This follows Valisure's 2019 tests showing Zantac forms a carcinogen,... 
Via Benzinga
Topics Lawsuit Whistleblower
News headline image
GSK's Experimental Asthma Drug Reduces Severe Attacks, Phase 3 Trial Data Shows ↗
GSK announced results from phase 3 trials SWIFT-1 and SWIFT-2, showing depemokimab's efficacy and safety in reducing severe asthma exacerbations. 
Via Benzinga
News headline image
GSK Completely Exits Sensodyne Toothpaste Maker Haleon In $1.6B Sale ↗
GSK is fully exiting its position and will no longer hold any ordinary shares in Haleon, maker of Sensodyne toothpaste and Advil painkillers. 
Via Benzinga
News headline image
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game ↗
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France,... 
Via Benzinga
News headline image
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade ↗
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics. 
Via InvestorPlace
Topics Intellectual Property
News headline image
Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025 ↗
These stocks to buy are expected to double by 2025 and could turn mundane market returns into something bigger with a willingness to bet. 
Via InvestorPlace
News headline image
Amazon Pours ~$1.3B Investment Into French Operations: Report ↗
Amazon's €1.2 billion investment marks a significant stride in bolstering its French presence, promising 3,000 new jobs. The move aligns with France's push for tech investment, showcased at the 'Choose... 
Via Benzinga
Topics Artificial Intelligence
News headline image
FDA Delays 'Important' Moderna Vaccine Review: William Blair Says 2025 Growth, '2026 Breakeven Story' Depends On It ↗
FDA update: Moderna's BLA for mRNA-1345, RSV vaccine, may face delay past May 12 deadline. But no safety concerns reported. 
Via Benzinga
News headline image
Moderna Dives Back Into Buy Zone After FDA Delays Its RSV Vaccine ↗
The FDA hasn't said there are any vaccine effectiveness, safety or quality issues that would prevent approval, Moderna says. 
Via Investor's Business Daily
News headline image
Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2 ↗
 
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
45 46 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today